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The majority were male, Caucasian, and insured. Average age
was 59 years old. Based on variable clustering, the XSQ pro-
duced three scales—Xerostomia Interference (9-items), Pain (5-
items), and Nausea and Vomiting Symptoms (3-items). Overall,
internal consistency was acceptable (Cronbach’s alpha coefﬁ-
cients ranged from 0.81–0.96). Construct validity was demon-
strated based on correlations between related items/scales.
Known groups validity was upheld, as HNC patients reported
statistically signiﬁcantly lower scale scores (worse functioning)
than NSCLC patients on all three domains (p < 0.05). As
expected, no statistically signiﬁcant differences were reported
between the groups on the FACT-G scales. CONCLUSIONS:
The XSQ was found to be reliable and valid in this population
and should be a useful tool for clinicians to monitor their
patients. Responsiveness will be evaluated in the future. The
ECHO Registry is currently ongoing.
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QUALITY OF LIFE OF NEWLY DIAGNOSED PROSTATE
CANCER PATIENTS IN A PUBLIC VS. PRIVATE SETTING
Jayadevappa R1, Chhatre S, Fomberstein K, Johnson KJ, Rosner A,
Bloom BS, Malkowicz SB
University of Pennsylvania, Philadelphia, PA, USA
OBJECTIVE: Demographic, clinical, social and economic
factors inﬂuence the Health Related Quality of Life (HRQOL)
and must be assessed in the management and treatment of
diverse prostate cancer (PC) patients. The study objective is to
analyze the variations in QoL of newly diagnosed PC patients
over the course of three months between public and private facil-
ities. METHODS: A total of 316 newly diagnosed PC patients
recruited from the urology clinics of a private urban academic
hospital and a veterans hospital completed SF-36 and UCLA-PCI
prior to treatment, and at 3-month follow-up. RESULTS:
General and Prostate-Speciﬁc QoL and demographics were com-
pared across public and private facilities using t-test and chi-sq.
Demographic characteristics varied signiﬁcantly between the two
groups. Privately-treated patients were predominantly Caucasian
(83.68%), whereas publicly-treated patients were predominantly
African American (66.23%, p < 0.0001). Privately-treated
patients had signiﬁcantly higher income and education levels,
and were signiﬁcantly more likely employed and married
(61.35% vs. 20.00%; 54.59% vs. 14.29%). Baseline mean
scores of general QoL demonstrated that publicly-treated
patients were substantially less healthy by physical, psychologi-
cal and social measures (mean physical function score of 47.53
compared to 70.46 for privately-treated patients (p < 0.0001)).
This was true for the PC-speciﬁc HRQoL also, though the dif-
ferences were smaller. After three months, the mean scores for
both groups declined from baseline levels though the groups’ rel-
ative divergence narrowed. Publicly-treated patients remained
substantially less healthy as indicated by general HRQoL scores.
However, for PC-speciﬁc QoL, their means scores on sexual and
urinary function, and sexual and urinary bother were signiﬁ-
cantly higher than privately-treated patients. CONCLUSIONS:
Baseline and 3-month HRQoL of newly diagnosed PC-patients
vary across different treatment settings. Further analysis into the
baseline determinants of QoL and their effect on subsequent
changes in QoL are crucial for effective management of prostate-
cancer. Acknowledgement: Supported by the DOD Prostate
Cancer Research Program DAMD17-02-1-0126.
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CASE-MATCHED CONTROLLED STUDY SHOWS MEN 
PREFER PROSTATE BRACHYTHERAPY TO CONFORMAL
RADIATION THERAPY
Kulkarni S1, Hanlon A1, Konski A2, Pollack A2, Horwitz E2, Raysor S1,
Bruner DW1
1Fox Chase Cancer Center, Cheltenham, PA, USA; 2Fox Chase Cancer
Center, Philadelpha, PA, USA
OBJECTIVES: Although there is no documented survival differ-
ence between 3-dimensional conformal radiation therapy
(3DCRT) and prostate-brachytherapy (PB), some studies suggest
a quality of life (QOL) advantage with PB. This study assessed
patient preferences for risk of impotence and incontinence after
PB and 3DCRT. METHODS: Preferences for PB were compared
to age, Gleason-grade and pretreatment-PSA matched controls
treated with 3DCRT, using a modiﬁed Time Trade-Off interview.
Men with PB (permanent I-125 implants) were 0.78 to 4.22
(median 2.24) years post treatment (PT) with 145Gy and men
with 3DCRT were 0.75 to 6.07 (median 2.33) years PT with 74
Gy (37 fractions) to the prostate. RESULTS: Preferences were
elicited from 51 men, (17 PB cases vs. 34 3DCRT matched con-
trols). Mean age for the cases and controls were 62.2 years and
63.6 years, respectively. Mean pretreatment-PSA and Gleason
scores were 7.1ng/ml and 5.9 for cases and 6.6ng/ml and 6.0 for
controls, respectively. There were no signiﬁcant differences
among cases and controls regarding race, education or income.
Differences in utilities were assessed using the Wilcoxon Test
(one-sided). Utilities for a 40% risk of impotence were 0.96
(SD.08) for cases and 0.91 (SD.16) for controls, which were not
signiﬁcant (p = 0.09). However, utilities for an 80% risk of impo-
tence were 0.93 (SD.12) for cases and 0.85 (SD.18) for controls
(p = 0.03). Utilities for a 30% risk of incontinence were 0.96
(SD.12) for cases and 0.85 (SD.22) for controls (p = 0.008). Util-
ities for a 10% risk of incontinence were 0.98 (SD.06) for cases
and 0.91 (SD.21) for controls (p = 0.05). CONCLUSIONS:
Patients treated with PB have signiﬁcantly higher utilities for
most levels of risk associated with impotence and incontinence
as compared to those treated with 3DCRT. This is possibly
related to either actual or perceived better sexual and urinary
QOL for PB as compared to 3DCRT.
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ARE HEALTH STATES “TIMELESS”? A TEST OF THE UTILITY
INDEPENDENCE ASSUMPTION USING A REPEATED
MEASURES DESIGN
Franic DM1, Gafni A2
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Hamilton, ON, Canada
OBJECTIVES: To test whether individuals’ responses to stan-
dard gamble (SG) and visual analogue scale (VAS) questions do
not depend on the time horizon of the health scenario presented.
METHODS: Face-to-face interviews were conducted in a con-
venience sample aged 24 to 59 years at a Southern University in
the US (n = 14). Preferences were estimated using SG and VAS.
Individuals rated their preferences for three health states of
varying severity of post chemotherapy nausea and vomiting
(PCNV) assuming different time horizons. Repeated measures
analysis of variance (ANOVA) were conducted (SX6X2) for each
health state to determine the affect of TIME (levels: 3 days, 3
months, 1 year, 5 years, 20 years and rest of life) and METHOD
(levels: SG and VAS) on preference. RESULTS: Analysis showed
that the time horizon used did affect an individual’s preference
rating for SG and VAS. For all three models tested (OP, ST, NV),
main effects TIME (F(5,65) = 10.71, F(5,65) = 13.85, F(5,65) =
17.40) and METHOD (F(1,13) = 34.56, F(1,13) = 58.01, F(1,13)
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= 17.80) were statistically signiﬁcant. For the least desirable
heath state (NV), TIME*METHOD interaction was also signif-
icant indicating the two factors were not independent of each
other, F(5,65) = 7.51. These results showed individuals rated the
same health state as less desirable (lower rating) for longer time
horizons and the preference elicitation method used made a dif-
ference. Furthermore, not only were health states not “timeless”,
but preference reversal also occurred resulting in fates perceived
as worse than death. CONCLUSIONS: For the majority of
respondents the utility independence assumption with respect to
time for SG and VAS methods did not hold. Similar to Bala et
al. (1999) and Franic et al. (2003) the results of this study indi-
cated preference weights as measured by SG and VAS techniques
were not “timeless”. Regardless of the preference measure used:
both SG and VAS yield higher scores for shorter time horizons.
CANCER
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THE BREAST CANCER SCREENING RATES OF GEORGIA
MEDICAID RECIPIENTS
Chen H, Kotzan JA, Martin BC
1The University of Georgia, Athens, GA, USA
OBJECTIVES: The primary objective was to evaluate the per-
formance of the Georgia Medicaid program for breast cancer
screening by comparing the GA Medicaid breast cancer-screen-
ing rate to the national benchmarks. The second objective was
to identify patient and provider characteristics associated with
the mammography use. METHODS: The study was a retro-
spective cohort study. The Health plan Employer Data and Infor-
mation Set (HEDIS) criteria were used to measure the breast
cancer screening rate for women aged 52 to 69. The 1999–2000
GA Medicaid administrative claim data, which included the eli-
gibility ﬁles patient link to the outpatient claims, were used. The
measurement year was 2000 and the 1999–2000 outpatient
claims were searched for mammography claims (ICD9 = V76.11
V76.12 CPT = 76090–76092). This rate was compared with the
National Committee for Quality Assurance (NCQA) breast
cancer-screening rates. Univariate and logistic analyses were used
to identify patient (physician visit level) and provider (physician
specialty and geographic location) characteristics associated with
breast cancer-screening rate. RESULTS: A total of 35,775
women aged 52–69 with two years continuous GA Medicaid eli-
gibility were identiﬁed. Nearly half (45.7%) of the subjects in
the cohort were African-American. Overall, 10,391 (29.1%) had
at least one mammography during the study period. This rate is
much lower than the national Medicaid median (55.6%) and the
national commercial median (74.8%) rates. Women aged 65
years or older had a lower breast cancer-screening rate as com-
pared with women under 65 (22.2% compared with 31.5%).
African-American women had mammography much less often
than caucasian women (18.1% compared with 53.4%). The
results of the logistic models predicting mammography use for
caucasian and African-American women will be reported. CON-
CLUSIONS: The GA Medicaid program breast cancer screening
rates were much lower than the national rates, particularly for
black women. Strategies to increase mammography use for indi-
gent women residing in GA should be sought.
CANCER
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OBJECTIVES: The importance of cancer outcomes research has
been well recognized. The purpose of this study was to examine
the current status of, and identify gaps in, colorectal cancer 
outcomes research. METHODS: Colorectal cancer outcomes
research articles published from 1999 to 2003 were retrieved
using a Medline search with keywords of “colorectal neoplasms
or colorectal cancer” and the following Medical Subject Heading
(MeSH): Economics, Cost and Cost Analysis, Survival, Quality
of life, Personal Satisfaction, Satisfaction, Mental Health,
Outcome Assessment (health care), Health Service Accessibility,
Health Service Research, Quality of Health Care, Quality Assur-
ance (health care), Quality Indicators (health care), Practice
Guideline, and Decision Making. The literature was limited to
the English language and human subjects. Articles excluded were
biological or pathological studies, clinical trials or reviews
mainly answering efﬁcacy-related questions, letters, comments
and editorials. The abstracts were reviewed and classiﬁed by
study designs, study endpoints and study impact levels ( 1) adds
to the knowledge base only; 2) affects practice polices; 3) inﬂu-
ences the delivery of care; 4) leads to changes in health outcomes,
as proposed by the Agency for Health care Research and
Quality)). Full-text articles were retrieved as needed for classiﬁ-
cation. RESULTS: A total of 3255 articles were retrieved by the
search, and 525 met the inclusion criteria for the analysis. Most
were retrospective cohort studies (216, 41.1%). The most
common endpoints were survival (371, 70.6%), followed by
quality of life (102, 19.4%), economic cost (81, 15.4%), and sat-
isfaction (17, 3.2%). A total of 481 articles (91.6%) were in level
1, 26 (5%) in level 2, 16 (3%) in level 3, and 2 (0.4%) in level
4. CONCLUSIONS: Most colorectal cancer outcomes studies
published in the last ﬁve years were focused on survival and rep-
resented impact level 1 research. Satisfaction was almost ignored
and hardly investigated. Outcomes research answering more
than survival questions and representing higher impact levels is
warranted.
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MEASURING CHEMOTHERAPY EFFECTIVENESS IN
NATURALISTIC SETTINGS: THE THREE FACES OF RELATIVE
DOSE INTENSITY
Kilgore KM, Zdanis MR
Cetus Group, LLC,Timonium, MD, USA
OBJECTIVES: In research on the effectiveness of chemotherapy,
a key measure of treatment delivery is average relative dose
intensity (ARDI), which summarizes delivered dosage per unit of
time, relative to an accepted standard. In clinical trials, where
dosages and timing are strictly controlled, the calculation and
use of ARDI are well-understood. In actual practice, however,
naturally-occurring events complicate the computation and
interpretation of this statistic: dosage levels can be reduced, treat-
ment cycles can be delayed or eliminated entirely, and the pre-
scribed regimen can differ materially from the published
standard. In recent naturalistic research studies and clinical per-
formance improvement programs, various alternative methods
of calculating ARDI have been presented, and have been given
